| Project/Area Number |
05454687
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Laboratory animal science
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
SATO Norimitsu Niigata University Sch.of Med.Assoc.Professor, 医学部, 助教授 (00111716)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUJISAWA Nobuyosi Niigata University Sch.of Med.Assistant, 医学部, 助手 (50199311)
|
|---|
| Project Period (FY) |
1993 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 1995: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1994: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1993: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | Tumor dormance / Adoptive immunotherapy against cancer / ddY substrain / Tumor-dormant mice / Tumor-resistant gene / Ehrlich tumor / 癌休暇 / tumor-dormancy / DDYマウス亜系 / 癌の養子免疫 / 固型癌の増殖抑制 / エールリッヒ腹水癌 |
|---|
| Research Abstract |
We concluded the following results.
1)Ehrlich ascites tumor (EAT) cells lack H-2 surface antigens.
2)However, non-MHC antigens may remain on the cell surface and some host defense mechanisms will be induced agaist EAT.
3)Some inbred strains of mice might have EAT-resistant genes, linkaged near H-2 gene locus. Number of EAT-resistant genes seem to be one or two.
4)Adoptive immune transfer of the EAT-dormant disposition of ddY-drm mice is possible by the EAT-activated spleen cells inoculation to ddY-prg mice. Cellular immunno-resistance, therefore, is involved in the mechanism.
5)Adoptive immunotherapy agaist EAT is only possible between ddY-drm and ddY-prg mice which may share a common genetic background other than H-2 or Ia loci through the history of two-way selection starting from the same basal stock colony .
6)Gene analysis of N2 mice will provide interesting results . In future, identification of EAT-resistant (EAT-dormant) gene, production of the Tg ddY-prg mice, and the gene transfer therapy against EAT will be interesting research objects .
|
